MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Other Products$67,131K (34.13%↑ Y/Y)Baqsimi$32,434K (-15.44%↓ Y/Y)Primatenemist$29,763K (2.45%↑ Y/Y)Epinephrine$19,213K (3.37%↑ Y/Y)Lidocaine$13,460K (-1.35%↓ Y/Y)Glucagon$9,170K (-56.00%↓ Y/Y)Revenues$171,171K (0.38%↑ Y/Y)Gross profit$70,322K (-17.51%↓ Y/Y)Cost of revenues$100,849K (18.26%↑ Y/Y)Income from operations$13,630K (-63.45%↓ Y/Y)Total operatingexpenses$56,692K (18.21%↑ Y/Y)Income before incometaxes$10,052K (-67.43%↓ Y/Y)Total non-operatingincome (expenses), net-$3,578K (44.36%↑ Y/Y)Interest income$2,400K (14.89%↑ Y/Y)Other income(expenses), net$575K (125.74%↑ Y/Y)Research and development$26,737K (33.05%↑ Y/Y)General andadministrative$18,028K (12.70%↑ Y/Y)Selling, distribution,and marketing$11,927K (0.51%↑ Y/Y)Net income$6,420K (-74.61%↓ Y/Y)Income tax provision$3,632K (-34.88%↓ Y/Y)Interest expense$6,553K (4.25%↑ Y/Y)
Income Statement
source: myfinsight.com

Amphastar Pharmaceuticals, Inc. (AMPH)

Amphastar Pharmaceuticals, Inc. (AMPH)